No Data
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Needham Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target
TD Cowen Initiates Viridian Therapeutics(VRDN.US) With Buy Rating
TD Cowen Initiates Coverage On Viridian Therapeutics With Buy Rating
Viridian Therapeutics: Buy Rating Due to Promising TED Therapy and Market Potential